Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

National Institute of Allergy and Infectious Diseases (NIAID)

Status and phase: Withdrawn; Phase 1

Conditions: HIV Infections; HIV Seronegativity

Treatments: Biological: QS-21; Biological: MN rsgp120/HIV-1; Biological: Aluminum hydroxide

Study type: Interventional

Funder types: NIH

Identifiers

NCT00000809

ACTG 279

11255 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.

Sex: All

Ages: 1 to 3 days old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Infants may be eligible for this study if they:

• Are 1 to 3 days old.